Innate Pharma: progress in hematology trial
The pharmaceutical company specifies that the cancers studied include relapsed/refractory acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, or high-risk myelodysplastic syndrome.
This progress in the trial has triggered a milestone payment of four million euros from Sanofi to Innate. SAR443579, the result of a collaboration between the two groups, has been granted Fast Track status by the US FDA for the treatment of AML.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction